Prospective Seroepidemiologic Study of Human Papillomavirus and Other Risk Factors in Cervical Cancer

Background: Several sexually transmitted infections (STI) have been reported to interact with human papillomavirus (HPV) in the etiology of cervical cancer. A large cohort study is required to obtain a both unbiased and stable estimate of their effects. Methods: Four major biobanks in the Nordic Countries containing samples from about 1,000,000 subjects were linked with nation-wide cancer registries. Serum samples from 604 women with invasive cervical cancer (ICC) diagnosed on average 10 years after sampling and 2,980 matched control women were retrieved and analyzed with serology for key STI. Results: Exposure to HPV16 was the strongest risk factor for cervical cancer [OR = 2.4; 95% confidence interval (CI), 2.0–3.0], particularly for squamous cell carcinoma (OR = 2.9; 95% CI, 2.2–3.7). HPV18 was strongly associated with increased risk for adenocarcinoma (OR = 2.3; 95% CI, 1.3–4.1). Baseline seropositivity for HPV16 did not confer any increased risk for HPV18 DNA-positive cancer and conversely HPV18 seropositivity had no association with HPV16 DNA-positive cancers. HPV6 had no effect on its own (OR = 1.1; 95% CI, 0.9–1.3), but had an antagonistic effect on the risk conferred by HPV16 (P < 0.01). Herpes simplex virus 2 had little or no association (OR = 1.1; 95% CI, 0.8–1.4). Previous exposure to Chlamydia trachomatis, as indicated by serum antibodies, had a strongly increased risk for cervical cancer (OR = 1.9; 95% CI, 1.5–2.3). Conclusions: A large prospective study has assessed the role of different STIs in cervical cancer. Impact: Prospective evidence supports cofactor role of some STI in cervical cancer. Cancer Epidemiol Biomarkers Prev; 20(12); 2541–50. ©2011 AACR.

[1]  S. Wacholder,et al.  Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. , 2011, The Journal of infectious diseases.

[2]  S. Wacholder,et al.  Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort. , 2010, Journal of the National Cancer Institute.

[3]  J. Palmgren,et al.  Prospective study of human papillomavirus and risk of cervical adenocarcinoma , 2010, International journal of cancer.

[4]  C. Wheeler,et al.  Incidence, Duration, and Reappearance of Type-Specific Cervical Human Papillomavirus Infections in Young Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[5]  C. Woodman,et al.  Cigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: A longitudinal study☆ , 2010, European journal of cancer.

[6]  M. Lehtinen,et al.  Population dynamics of serologically identified coinfections with human papillomavirus types 11, 16, 18 and 31 in fertile‐aged Finnish women , 2009, International journal of cancer.

[7]  M. Schiffman,et al.  The Use of Human Papillomavirus Seroepidemiology to Inform Vaccine Policy , 2009, Sexually transmitted diseases.

[8]  E. Pirog,et al.  Comprehensive analysis of Human Papillomavirus and Chlamydia trachomatis in in-situ and invasive cervical adenocarcinoma. , 2009, Gynecologic oncology.

[9]  M. Lehtinen,et al.  Is smoking an independent risk factor for invasive cervical cancer? A nested case-control study within Nordic biobanks. , 2008, American journal of epidemiology.

[10]  M. Leinonen,et al.  Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors , 2007, International journal of cancer.

[11]  Pär Stattin,et al.  Nordic biological specimen banks as basis for studies of cancer causes and control – more than 2 million sample donors, 25 million person years and 100 000 prospective cancers , 2007, Acta oncologica.

[12]  S. Franceschi,et al.  Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. , 2006, Vaccine.

[13]  H. Trottier,et al.  Human Papillomavirus Infections with Multiple Types and Risk of Cervical Neoplasia , 2006, Cancer Epidemiology Biomarkers & Prevention.

[14]  V. Beral,et al.  Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies , 2006, International journal of cancer.

[15]  Peter J. F. Snijders,et al.  Bead-Based Multiplex Genotyping of Human Papillomaviruses , 2006, Journal of Clinical Microbiology.

[16]  J. Dillner,et al.  Chlamydia trachomatis infection and persistence of human papillomavirus , 2005, International journal of cancer.

[17]  J. Dillner,et al.  Comparison between the Hybrid Capture II Test and a PCR-Based Human Papillomavirus Detection Method for Diagnosis and Posttreatment Follow-Up of Cervical Intraepithelial Neoplasia , 2005, Journal of Clinical Microbiology.

[18]  R. Brunham,et al.  Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine , 2005, Nature Reviews Immunology.

[19]  R. Peeling,et al.  Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case‐control study , 2004, International journal of cancer.

[20]  J. Palefsky,et al.  Chlamydia trachomatis, Herpes Simplex Virus 2, and Human T-Cell Lymphotrophic Virus Type 1 Are Not Associated With Grade of Cervical Neoplasia in Jamaican Colposcopy Patients , 2003, Sexually transmitted diseases.

[21]  Joakim Dillner,et al.  Evaluation of cost-precision rations of different strategies for ELISA measurement of serum antibody levels. , 2002, Journal of immunological methods.

[22]  S. Franceschi,et al.  Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. , 2002, Journal of the National Cancer Institute.

[23]  F. Wiklund,et al.  A population‐based prospective study of Chlamydia trachomatis infection and cervical carcinoma , 2002, International journal of cancer.

[24]  Joakim Dillner,et al.  Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the nordic countries. , 2002, American journal of epidemiology.

[25]  M. Lehtinen,et al.  A prospective study of the relationship between prediagnostic Human Papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas , 2002, British Journal of Cancer.

[26]  P. Fuchs,et al.  Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. , 2001, The New England journal of medicine.

[27]  P. Simpson,et al.  Statistical methods in cancer research , 2001, Journal of surgical oncology.

[28]  P. Saikku,et al.  Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. , 2001, JAMA.

[29]  J. Dillner,et al.  Correlates of the spread of human papillomavirus infection. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[30]  F. Wiklund,et al.  Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. , 2000, The Journal of infectious diseases.

[31]  J. Dillner.  The serological response to papillomaviruses. , 1999, Seminars in cancer biology.

[32]  J. Dillner,et al.  Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. , 1999, The Journal of general virology.

[33]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[34]  T. Bjørge,et al.  No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11 , 1999, International journal of cancer.

[35]  T. Bjørge,et al.  Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. , 1997, Journal of the National Cancer Institute.

[36]  J. Dillner,et al.  Human papillomavirus antibody responses among patients with incident cervical carcinoma , 1997, Journal of medical virology.

[37]  C. Meijer,et al.  A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings , 1997, Journal of clinical microbiology.

[38]  F. Wiklund,et al.  A prospective study on the risk of cervical intra‐epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears , 1996, International journal of cancer.

[39]  D. Lowy,et al.  A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. , 1994, Journal of the National Cancer Institute.

[40]  K. Macrae,et al.  A colposcopic case-control study of cervical squamous intraepithelial lesions in women with anogenital warts. , 1992, Genitourinary medicine.

[41]  S Lemeshow,et al.  Confidence interval estimation of interaction. , 1992, Epidemiology.

[42]  W. Reeves,et al.  Evaluation of a test based on baculovirus-expressed glycoprotein G for detection of herpes simplex virus type-specific antibodies. , 1991, The Journal of infectious diseases.

[43]  B. Vestergaard,et al.  Elisa for Herpes Simplex Virus (HSV) Type‐Specific Antibodies in Human Sera Using HSV Type 1 and Type 2 Polyspecific Antigens Blocked with Type‐Heterologous Rabbit Antibodies , 1979, Acta pathologica et microbiologica Scandinavica. Section B, Microbiology.

[44]  M. Abba,et al.  Chlamydia trachomatis and Human papillomavirus infections in cervical disease in Argentine women. , 2005, Gynecologic oncology.

[45]  C. Wheeler,et al.  Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix. , 2003, American journal of obstetrics and gynecology.

[46]  N. Breslow,et al.  Statistical methods in cancer research: volume 1- The analysis of case-control studies , 1980 .